Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Humana Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $46.6B | |
|---|---|---|
| P/E (forward) | 24.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $83.06B | $92.87B | $106.37B | $117.76B | $129.66B | +11.8% |
| Gross profit | $14.45B | $17.23B | $18.05B | $17.15B | $18.85B | +6.9% |
| Operating income | $3.15B | $3.80B | $4.01B | $2.56B | $2.70B | -3.7% |
| Net income | $2.93B | $2.81B | $2.49B | $1.21B | $1.19B | -20.2% |
| EPS (diluted) | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 | -18.8% |
| EBITDA | $4.46B | $4.81B | $4.73B | $3.26B | $2.91B | -10.1% |
| R&D | — | — | — | — | — | — |
| SG&A | $10.12B | $12.67B | $13.19B | $13.70B | $15.45B | +11.2% |
Recent company headlines from major financial publishers.
The Base scenario models a multi-year operational turnaround where disciplined Medicare Advantage contract repricing and administrative cost controls lift Insurance segment operating margins toward mid-cycle norms. The Base target of $264.45 carries a 55.0% probability, implying an expected return of -31.9% from $388.36 (as of 2026-10-02). Confirmation requires steady progression in segment margins across quarterly checkpoints, while failure to restore underwriting profitability by FY2027 would disconfirm this trajectory.
The Bull scenario models accelerated margin expansion as Medicare Advantage repricing outpaces medical cost inflation, Star rating quality bonuses are successfully remediated, and CenterWell clinical operations scale rapidly across external payer networks. This optimistic path yields a target of $334.97 with a 20.0% probability, representing an implied return of -13.7% relative to $388.36. Disconfirmation would emerge if medical utilization surges further or if member attrition accelerates in repriced markets.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.5% | $284 | $291 | $299 | $307 | $317 |
| 8.0% | $268 | $274 | $280 | $287 | $294 |
| 8.5% | $255 | $259 | $264 | $270 | $276 |
| 9.0% | $243 | $247 | $251 | $256 | $261 |
| 9.5% | $233 | $236 | $240 | $243 | $248 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
